) t z8 |3 K; {. n! ~" f, n
临床上有依维莫司联合EGFR TKI作为易/特耐药之后的方案的研究:1 g. T" H; ^. p Z7 {
Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer. ' p. d& J9 y2 k% k8 dhttp://www.ncbi.nlm.nih.gov/pubmed/22968184 * Q& W1 `, m+ D. e3 E" C, n 3 {' f) e1 @- I5 L) z% `( S$ |依维莫司联合吉非替尼抑制非小细胞肺癌细胞系的效果和作用机制0 ?6 |( `, \; f1 |& X9 e' p http://d.wanfangdata.com.cn/Thesis_Y1770447.aspx